Mayo Clinic | Strategic Alliance Partners

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the multifaceted role of oncology pharmacists in diverse care settings, emphasizing their collaboration in treatment decisions and adaption in the evolving landscape of cancer care.

Pharmacists' expertise is crucial in educating patients about regulatory changes, helping them navigate alternative formulations, and providing insights into evidence-based choices.

With gastrointestinal-based adverse effectss for rivastigmine and other cholinesterase inhibitors, a weight of <50 and <55 kg respectively leads to an increased risk for toxicities.

This latest revision introduces a new set of drug criteria, refines the existing ones, and enhances the overall formatting to ensure increased ease of use and clarity for its recommendations.

Investigators also found that the results demonstrated lower death and hospitalization rates for those with advanced heart failure treated with cell therapy.

In addition to growing rates of STIs, there is concern for antimicrobial resistance to STIs.

Calvin Tucker, PharmD, MBA, FCCM, FFSHP, Pharmacy Manager for the Cancer Care Pharmacy discusses the unique and valuable role pharmacist have within the health care community

Amber Bush, PharmD, RPh, BCPS, BCCCP, pharmacy research coordinator for Mayo Clinic discusses the future of pharmacy through her role within research clinical trials

The assistant program director at Mayo Clinic discusses the significance of pharmacists’ role in health care, changes throughout the industry, and her passion for mentoring pharmaceutical students.

It is vital for health care teams to recognize the signs and symptoms of antiphospholipid syndrome and to identify the severity of a patient’s diagnosis based on their aPL profile.

An increase in cannabis use has led to growing concerns surrounding interactions between its components, THC and CBD, and prescription medications.

Pharmacists play a key role in the management of modern monoclonal antibody treatments for Alzheimer disease.

Pharmacists play a key role in migraine management, therefore, awareness of menstrual migraine-specific prophylaxis is important.

Pharmacists working with patients with mental health conditions are able to optimize medication use and improve adherence.

Major pharmacogenomics organizations continue to recognize the potential relevance of pharmacogenomics for psychiatric medication management, mainly due to its effects on pharmacokinetics.

Therapeutic drug monitoring is a growing and vital area for pharmacists to become involved in to increase patient success with inflammatory bowel disease remission.

STRONG-HF aimed to study whether rapid-dose escalation of guideline-directed heart failure medications was more beneficial than usual care.

Available pharmacological therapies have shown high efficacy in achieving weight loss.

Since the 2018 guideline’s publication, additional non-statin therapies such as bempedoic acid, evinacumab, and inclisiran, have been approved by the FDA for the management of hypercholesterolemia.

In the treatment of heart failure with reduced ejection fraction, combination therapy is the most effective in reducing all-cause death.

Data show that dose-response relationships and long-term safety of ICS in people with chronic obstructive pulmonary disease are unclear and require further investigation.

The implementation of genetic testing for patients prescribed medications associated with progressive multifocal leukoencephalopathy is likely to improve safety outcomes.

Different guidelines have notable differences between equivalency dosing of proton pump inhibitors (PPI), resulting in confusion and a lack of confidence between medical professionals recommending one PPI over another.

Finerenone is a first in class nonsteroidal mineralocorticoid receptor antagonist indicated in adults with chronic kidney disease associated with type 2 diabetes mellitus.

Trastuzumab deruxtecan was approved by the FDA for HER2-low breast cancer treatment in 2022 and could also benefit some patients with hormone receptor-positive or triple-negative disease.

Furosemide exhibits diuretic action by inhibiting sodium and chloride reabsorption in the proximal and distal tubules and the loop of Henle.

As evidence for omega-3 continues to develop, pharmacists remain poised to guide patients toward the most indicated, safe, effective, and convenient options available.

Cabotegravir showed promising results in preventing HIV transmission in men, women, and transgender women with similar rates of adverse events to oral PrEP options.

New continuous glucose monitor systems provide additional support and quality of life improvements for patients with diabetes.